Quick Answer
NovoCure Ltd reported Total Assets of $804.33 million for the year ending 2025.
- NovoCure Ltd showed a decrease of -35.2% in Total Assets from 2024 to 2025.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $173.78 million | Q1 2016: $279.02 million | Q2 2016: $250.52 million | Q3 2016: $291.09 million | Q1 2017: $264.63 million | Q2 2017: $257.04 million | Q3 2017: $262.28 million | Q1 2018: $303.48 million | Q2 2018: $309.88 million | Q3 2018: $315.51 million | Q1 2019: $370.26 million | Q2 2019: $406.19 million | Q3 2019: $443.86 million | Q1 2020: $502.45 million | Q2 2020: $528.94 million | Q3 2020: $431.05 million | Q1 2021: $1.07 billion | Q2 2021: $1.10 billion | Q3 2021: $1.12 billion | Q1 2022: $1.15 billion | Q2 2022: $1.16 billion | Q3 2022: $1.17 billion | Q1 2023: $1.17 billion | Q2 2023: $1.16 billion | Q3 2023: $1.15 billion | Q1 2024: $1.12 billion | Q2 2024: $1.21 billion | Q3 2024: $1.22 billion | Q1 2025: $1.25 billion | Q2 2025: $1.25 billion | Q3 2025: $1.36 billion.
- Over the full 12 years of available data (2014 to 2025), NovoCure Ltd's Total Assets has grown by 582.3%.
- Historical annual values: Fiscal year 2025: $804.33 million | Fiscal year 2024: $1.24 billion | Fiscal year 2023: $1.15 billion | Fiscal year 2022: $1.19 billion | Fiscal year 2021: $1.14 billion | Fiscal year 2020: $1.05 billion | Fiscal year 2019: $479.45 million | Fiscal year 2018: $339.79 million | Fiscal year 2017: $265.30 million | Fiscal year 2016: $282.08 million | Fiscal year 2015: $307.34 million | Fiscal year 2014: $117.88 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: